The ELF panel: A new crystal ball in hepatology?

Gut

Volumn 59, Issue 9, 2010, Pages 1165-1167

  Pinzani, Massimo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; HYALURONIC ACID; METALLOPROTEINASE; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER;

ALCOHOL LIVER DISEASE; CHRONIC LIVER DISEASE; FIBROGENESIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; BLOOD; DISEASE COURSE; LIVER CIRRHOSIS; PROGNOSIS;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS; PROGNOSIS;

EID: 77956112723     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.214932     Document Type: Note

References (11)

1. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 2010;59:861-6.
2. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 2004;36:231-42. (Pubitemid 41115470)
3. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13. (Pubitemid 39575849)
4. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-60. (Pubitemid 351280713)
5. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in paediatric non-alcoholic fatty liver disease. Gastroenterology 2009;136:160-7.
6. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis (ELF) assay. Hepatology 2008;48:1549-57.
7. Parkes J, Roderick P, Harris S, et al. Enhanced Liver Fibrosis (ELF) Test can predict clinical outcomes in patients with mixed aetiology chronic liver disease. Gut 2010;59:1245-51.
8. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52:1887-96. (Pubitemid 44470696)
9. Ngo Y, Benhamou Y, Thibault V, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS One 2008;3:e2573.
10. Naveau S, Gaudé G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009;49:97-105.
11. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of hcv-infected individuals with and without HIV infection. Am J Gastroenterol. Published Online First: 23 February 2010. doi:10.1038/ajg.2009.746.